RESUMO
OBJECTIVE@#To evaluate the effect of doxorubicin and its pegylated liposomal formulation (Doxil, Caelyx) on in vitro susceptibility of promastigote and amastigote stages of Leishmania major.@*METHODS@#Throughout in vitro assays the IC was calculated in the promastigotes and amastigotes forms in J774 macrophage cell line. Also as cytotoxicity in J774 cell line macrophages.@*RESULTS@#Doxorubicin and Doxil showed the same activity against promastigote form with IC values of 10.49 μg/mL and 9.63 μg/mL, respectively. Similarly, the amastigote stage was susceptible at concentration of at least 1 μg/mL when compared to positive control (P < 0.0001). Also, cytotoxicity assay against macrophage revealed no toxicity on the host cells at IC concentrations.@*CONCLUSIONS@#Our findings demonstrated the efficacy of both doxorubicin and its pegylated liposomal formulation on L. major at low concentrations. Further researches are needed for evaluating the safety of drugs in animal model particularly as topical formulation.
RESUMO
Objective To evaluate the effect of doxorubicin and its pegylated liposomal formulation (Doxil, Caelyx) on in vitro susceptibility of promastigote and amastigote stages of Leishmania major. Methods Throughout in vitro assays the IC
RESUMO
ABSTRACT Liposomes, the vesicles of phospholipid bilayer, can encapsulate both hydrophilic and lipophilic drugs and protect them from degradation. Liposomes have been extensively studied and continue to create intense interest in research since their discovery in the mid-1960s. Since then, liposomes have been considered to be the most successful nanocarriers for drug deliver and have made their way to the market. Currently, a number of liposomal formulations are on the marker for cancer treatment and many more are in pipe line. This review discusses about the liposome components, methods of preparation, drug encapsulation mechanism and the potential therapeutic applications of liposomes in cancer therapy.